ZOLL Announces Closing of Acquisition of Select Vyaire Ventilator Product Lines

With the acquisition complete, ZOLL will immediately make available to customers the bellavista®, fabian®*, LTV®, and 3100 HFOV product lines alongside ZOLL’s other respiratory care offerings. For these acquired product lines, all ventilators and associated consumables, service parts, accessories, and service program offerings will continue to be sold where currently available. Existing Vyaire contact channels will remain available for use during a transition period. Customers can also contact ZOLL at ventsales@zoll.com.

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it successfully completed its previously announced acquisition of certain assets of Vyaire Medical’s ventilator business.

With the acquisition complete, ZOLL will immediately make available to customers the bellavista®, fabian®*, LTV®, and 3100 HFOV product lines alongside ZOLL’s other respiratory care offerings. For these acquired product lines, all ventilators and associated consumables, service parts, accessories, and service program offerings will continue to be sold where currently available. Existing Vyaire contact channels will remain available for use during a transition period. Customers can also contact ZOLL at ventsales@zoll.com.

“ZOLL’s acquisition of select Vyaire ventilator product lines is an exciting opportunity for our customers and our company,” said Jon Rennert, CEO of ZOLL. “We now have the ability to serve even more patients and customers, furthering our mission of improving patient outcomes and helping save lives.”

*Not available for sale in the U.S.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

April 30, 2025

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

April 24, 2025

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.